Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks 
UOB Q1 Profit Meets Expectations as Loan Growth Offsets Lower Interest Rates 
JD Sports Backs Nike CEO Elliott Hill Amid Brand Turnaround Efforts 
Orsted Q1 EBITDA Beats Expectations Despite U.S. Impairments 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Arm Stock Drops Despite Strong AI Chip Demand and Earnings Beat 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
Shell Q1 Profit Surges to Two-Year High as Dividend Rises Despite War-Driven Debt Pressure 
WALTHAM, Mass., April 27, 2018 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will participate in the following investor conferences:
- Deutsche Bank Annual Health Care Conference
Tuesday, May 8, 2018 at 8:40 a.m. ET
Location: Boston, MA - Bank of America Merrill Lynch Health Care Conference
Tuesday, May 15, 2018 at 4:20 p.m. PT (7:20 p.m. ET)
Location: Las Vegas, NV
To access the live webcasts, please visit the Investors section of the company’s website at www.amagpharma.com. A replay of each event will be archived on the site for 30 days.
About AMAG
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our currently marketed products support the health of patients in the areas of maternal and women’s health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc. CBR® is a registered trademark of Cbr Systems, Inc.
AMAG Pharmaceuticals Contact:
Christi Waarich
Associate Director, Investor Relations
617-498-7638
